Actively Recruiting
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Led by Jun Guo · Updated on 2025-03-05
50
Participants Needed
1
Research Sites
228 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
CONDITIONS
Official Title
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed unresectable or metastatic stage III or IV melanoma
- Genetic mutation or alteration in homologous recombination (HR) pathway genes or SF3B1
- Measurable disease based on RECIST 1.1 criteria
- ECOG performance status of 0 to 1
- Recovery from all adverse events of previous therapies to Grade 1 or baseline
- Expected overall survival longer than 3 months
- Male or non-pregnant female able to use birth control during treatment
You will not qualify if you...
- Prior treatment with a PARP inhibitor
- Hypersensitivity to fluzoparib, camrelizumab, or temozolomide
- Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy exceeding 10 mg daily prednisone equivalent within 7 days before study drug
- Receiving any other immunosuppressive therapy within 7 days before study drug
- History of other malignancies within 5 years before starting trial treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jun Guo
CONTACT
B
Bin Lian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here